Medication-Related Burden among Iraqi Patients with Crohn’s Disease: A Cross Sectional Study
DOI:
https://doi.org/10.31351/vol33iss4pp89-95Keywords:
Medication-Related Burden, Iraq, Crohn’s Disease, inflammatory bowel disease, living with medicine questionnaireAbstract
Crohn’s disease is an inflammatory bowel disease that is characterized by chronic inflammation of any part of the gastrointestinal tract, has a progressive and destructive course and is increasing in incidence worldwide. Medical treatment of Crohn’s disease is usually divided into remission induction therapy and remission maintenance therapy. Medication-related burden is a new concept focused on the negative experiences resulting from taking medicines. The aims of the current study were to measure medication-related burden among a sample of Iraqi patients with Crohn’s disease, and to determine any associations between medication-related burden and some patient factors. The present study was cross-sectional conducted at ‟Gastroenterology and Hepatology Teaching Hospital/ Medical City / Baghdad / Iraq” during December 2022 to May 2023. The Arabic version of living with medicine questionnaire was used to measure medication-related burden experienced by the patients. 94 Crohn’s disease were included [Males =58 (61.7%), Females=36 (38.3%)] with mean age (31.9±10.8 years). The mean of total burden score was (102.7 ± 20.6) with more than half (54.3%) of the patients experienced a minimum degree of medication burden, followed by moderate burden (29.8%), no burden (8.5%) and high burden (7.4%). Three domains showed the highest mean of burden scores: “Cost Related Burden”, “concerns about medicines use” and “Autonomy to vary regimen”. Total burden score, “side effects of medicines” and “effectiveness of prescribed medications” domains were significantly lower in remission patients compared to active cases. In conclusion, a large proportion of the Crohn’s disease have experienced varying degrees of medication-related burden. Disease activity was independently correlated with total burden score.
How to Cite
Publication Dates
Received
Revised
Accepted
Published Online First
References
Kimberley W, Marzyeh A, Vera , Gerard D, Behrooz Z. Inflammatory Bowel Diseases: Review of Known Environmental Protective and Risk Factors Involved. Inflamm Bowel Dis. 2017;23:1499–1509.
H Alhagamhmad M, T Leach S, A Lemberg D, S Day A. Changing Patterns in the Epidemiology of Crohn Disease. Journal of Gastroenterology and Hepatology Research. 2015;4(11):1805–9.
Ad’hiah AH, Hessan EB, Shahab BA. Interleukin-1 single nucleotide polymorphisms as risk factors for susceptibility of inflammatory bowel disease: an Iraqi Arab population-based study. Alexandria Journal of Medicine. 2019 Jan 2;55(1):1-6.
Abdulamir AS, Zaman MZ, Hafidh RR, Abu Bakar F. The Role of Diet, Prebiotic and Probiotic in the Development and Management of Inflammatory Bowel Diseases (IBD). Chapter 14 in Karoui S. Inflammatory Bowel Disease-Advances in Pathogenesis and Management. 2012. [cited 2023 Aug 5]. Available from: https://books.google.iq/books?id=mZmfDwAAQBAJ&pg=PA249&dq=The+Role+of+Diet
Mohammed BI, Amin BK. Sociodemographic characteristics, smoking, and family history of patients with inflammatory bowel disease, northern part of Iraq. Med J Babylon. 2022;19:615-9.
Mosli M, Alawadhi S, Hasan F, Abou Rached A, Sanai F, Danese S. Incidence, Prevalence, and Clinical Epidemiology of Inflammatory Bowel Disease in the Arab World: A Systematic Review and Meta-Analysis. Inflammatory Intestinal Diseases. 2021;6(3):123–31.
Shivashankar R, Lichtenstein GR. Mimics of Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2018 Jun 27;24(11):2315–21.
Zhang YZ, Li YY. Inflammatory bowel disease: Pathogenesis. World Journal of Gastroenterology. 2014;20(1):91.
Gade A K, Douthit N T, Townsley E . Medical Management of Crohn's Disease. Cureus. 2020;12(5): e8351.
Zidan A, Awisu A, El-Hajj MS, Al-Abdulla SA, Figueroa DCR, Kheir N. Medication-Related Burden among Patients with Chronic Disease Conditions: Perspectives of Patients Attending Non-Communicable Disease Clinics in a Primary Healthcare Setting in Qatar. Pharmacy. 2018 Aug 13;6(3):85.
Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open. 2016 Feb;6(2):e010035.
Wang Y, Li X, Jia D, Lin B, Fu B, Qi B, et al. Exploring polypharmacy burden among elderly patients with chronic diseases in Chinese community: a cross-sectional study. BMC Geriatrics. 2021;21(1):1-9.
Hawraa KA, Dheyaa JK, Faiq IG, Laith GS. Assessment of medication-related burden among a sample of Iraqi patients with systemic lupus erythematosus and its relationship with disease activity: a cross-sectional study. F1000Research. 2022 Nov 1;11(970):970.
Ayman JN, Dheyaa JK, Muqdad AA. Medication-related burden among patients with diabetes mellitus and its relation to diabetic control parameters: an observational study. F1000Research. 2022 Sep 28;11:1112.
Rwnk KJ, Dheyaa JK, Mohammed HM, Laith GS. Medication-related burden among Iraqi patients with rheumatoid arthritis: An observational study. F1000Research. 2022 Sep 13;11:1047.
Zidan A. Medication-related burden among patients with chronic disease conditions: perspectives of patients attending non-communicable disease clinics in a primary healthcare setting in Qatar. [master's thesis] [Qatar university. College of pharmacy]; 2017.
Buckley JP, Kappelman MD, Allen JK, Van Meter SA, Cook SF. The Burden of Comedication Among Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2013 Dec;19(13):2725–36.
Odeyinka O, Alhashimi R, Thoota S, et al. The Role of Capsule Endoscopy in Crohn's Disease: A Review. Cureus. 2022; 14(7): e27242.
Nisreen JJ, Dheyaa JK, Nawal MF, Hayder AF. Assessment of health-related quality of life of Iraqi patients with inflammatory bowel disease. Int. J. Res. Pharm. Sci.2018; 9(3), 829-835.
Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24:319–28.
Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010;31:693–707.
Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215–26.
Valk ME van der, Mangen MJJ, Leenders M, Dijkstra G, Bodegraven AA van, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut . 2014;63(1):72–9.
Park KT, Colletti RB, Rubin DT, Sharma BK, Thompson A, Krueger A. Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States. Am J Gastroenterol. 2016;111:15–23.
Nisreen JJ, Dheyaa JK, Nawal MF. Belief about Medications among Sample of Iraqi Patients with Inflammatory Bowel Disease. Iraqi Journal of Pharmaceutical Sciences. 2018 Dec 6;32–41.
Liverani E, Scaioli E, Digby RJ, Bellanova M, Belluzzi A. How to predict clinical relapse in inflammatory bowel disease patients. World Journal of Gastroenterology. 2016 Jan 21;22(3):1017–33.
Hussenbux A, De Silva A. Steroids in inflammatory bowel disease: a clinical review. Gastrointestinal Nursing. 2021 Feb 2;19(1):28–33.
Bruscoli S, Febo M, Riccardi C, Migliorati G. Glucocorticoid Therapy in Inflammatory Bowel Disease: Mechanisms and Clinical Practice. Frontiers in Immunology. 2021 Jun 3;12.
Downloads
Published
License
Copyright (c) 2024 Iraqi Journal of Pharmaceutical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
